Jørgen Bjerggaard Jensen
Clinical trials sponsored by Jørgen Bjerggaard Jensen, explained in plain language.
-
Blood test triggers early attack on returning bladder cancer
Disease control OngoingThis study tests if giving immunotherapy earlier improves outcomes for bladder cancer patients. It involves 154 adults who had their bladder removed and now show tiny signs of cancer returning in their blood, even before scans can see it. Researchers use a blood test to detect th…
Phase: PHASE2 • Sponsor: Jørgen Bjerggaard Jensen • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Shorter treatment time may ease bladder cancer therapy side effects
Symptom relief OngoingThis study is testing if reducing the amount of time a standard bladder cancer treatment (BCG) stays in the bladder can make side effects less severe. It involves 314 patients with high-risk non-muscle invasive bladder cancer across Nordic countries. The goal is to help more pati…
Phase: PHASE4 • Sponsor: Jørgen Bjerggaard Jensen • Aim: Symptom relief
Last updated Apr 01, 2026 14:43 UTC